表紙:精神障害薬の世界市場の分析 (2021年~2031年):医薬品クラス別、適応症別、エンドユーザー別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ
市場調査レポート
商品コード
1001227

精神障害薬の世界市場の分析 (2021年~2031年):医薬品クラス別、適応症別、エンドユーザー別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ

Mental Disorder Drugs Market Report 2021-2031: Forecasts by Drug Class, by Indication, by End-user, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 429 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=169.13円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

精神障害薬の世界市場の分析 (2021年~2031年):医薬品クラス別、適応症別、エンドユーザー別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ
出版日: 2021年02月12日
発行: Visiongain Reports Ltd.
ページ情報: 英文 429 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の精神障害薬の市場規模は、予測期間中に好調なCAGRで拡大すると予測されています。うつ病、双極性障害、不安神経症、統合失調症などの精神障害の蔓延は、精神障害薬の需要を促進する主な要因となっています。新興諸国におけるメンタルヘルスの意識の高まり、治療および維持療法のための精神障害薬の採用、メンタルヘルスの分野における大手製薬会社による研究開発投資の増加などもまた市場成長を後押しする別の要因となっています。さらに、COVID-19のパンデミックは、精神障害薬市場に大きな影響を及ぼしています。 COVID-19のパンデミックは、失業、金融危機、健康問題、およびストレスによる精神障害の発生率の増加をもたらしました。したがって、精神障害薬の需要は予測期間中に増加すると予想されています。

当レポートでは、世界の精神障害薬市場について分析し、製品の概要や市場の基本構造・最新情勢、主な成長・抑制要因、市場規模の動向見通し (2021年~2031年)、および地域別・主要国の詳細動向、主要企業のプロファイル、COVID-19からの影響シナリオ、といった情報を提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場力学

  • 成長要因
    • 先進的な精神障害薬の開発
    • 精神障害の有病率の増加
    • メンタルヘルスケア意識の高まり
  • 抑制要因
    • 新薬の開発の増加
    • 精神障害の社会的不名誉
    • 新薬承認のための厳格な規制ガイドライン
  • 市場機会
    • 市場成長を支援する精神障害の最先端の治療法に対する需要の高まり
    • 老齢人口の増加
  • 動向
    • 市場参加企業による合併、合意、買収
    • 新薬の発売予定が市場成長を促進する見込み
  • SWOT分析
    • 強み:精神障害市場の最もダイナミックな分野
    • 弱点
    • 市場機会
    • 脅威
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力:中程度
    • バイヤーの交渉力:中程度
    • 競争企業間の敵対関係:高い
    • 新規参入業者の脅威:中程度
    • 代替品の脅威:中程度
  • PEST分析
    • 精神障害薬市場に影響を与える政治的要因
    • 精神障害薬市場に影響を与える経済的要因
    • 精神障害薬市場に影響を与える社会的要因
    • 精神障害薬市場に影響を与える技術的要因

第4章 世界市場予測、2021年~2031年

  • 世界市場予測、2021年~2031年

第5章 COVID-19の影響:世界の精神障害薬市場

  • 「V」字型の回復-急速な衰退-鋭いボロウ-急速な回復
  • 「U」字型の回復-早い段階で急速に低下し、その後ゆっくりと-下部で徐々に回復する-最初は回復が遅い-後で回復するのが速い
  • 「W」字型の回復-急速な衰退-急速な回復-ウイルスの再発-もう1つの急激な衰退-回復
  • 「L」字型の回復-急速な衰退-その後の成長の鈍化

第6章 医薬品クラス別市場規模予測、2021年~2031年

  • 世界のSSRIセグメント:収益予測、2021年~2031年
    • 最大の収益グロスセグメント
    • 回復予測(V、U、W、L)
  • 世界のSNRIセグメント:収益予測、2021年~2031年
    • 精神障害の治療のためのこれらの薬の採用の増加
    • 回復予測(V、U、W、L)
  • 世界の非定型抗精神病薬セグメント:収益予測、2021年~2031年
    • 非定型抗精神病薬セグメントは、有利な成長率で成長する見込み
    • 回復予測(V、U、W、L)
  • 世界のTCAセグメント:収益予測、2021年~2031年
    • TCA:重度のうつ病の治療に役立つ
    • 回復予測(V、U、W、L)
  • 世界のSARIセグメント:収益予測、2021年~2031年
    • SARI:主にMDDの治療に使用
    • 回復予測(V、U、W、L)
  • 世界のベンゾジアゼピンセグメント:収益予測、2021年~2031年
    • ベンゾジアゼピンセグメント:予測期間中に安定成長する見込み
    • 回復予測(V、U、W、L)
  • 世界のMAOIセグメント:収益予測、2021年~2031年
    • MAOIセグメント:予測期間中に好調なCAGRで推移する見通し
    • 回復予測(V、U、W、L)
  • 世界のその他セグメント:収益予測、2021年~2031年
    • 先進的な薬剤に対する需要の高まりがセグメントの成長を推進
    • 回復予測(V、U、W、L)

第7章 適応症別市場規模予測、2021年~2031年

  • 世界のうつ病セグメント:収益予測、2021年~2031年
    • 最大の収益グロスセグメント
    • 回復予測(V、U、W、L)
  • 世界の統合失調症セグメント:収益予測、2021年~2031年
    • 世界中で統合失調症の有病率が高まると、セグメントの成長が促進
    • 回復予測(V、U、W、L)
  • 世界の双極性障害セグメント:収益予測、2021年~2031年
    • 双極性障害の治療のためのジェネリック医薬品の採用
    • 回復予測(V、U、W、L)
  • 世界の心的外傷後ストレス障害セグメント:収益予測、2021年~2031年
    • 治療的に進歩した精神障害薬の開発における研究開発費の増加
    • 回復予測(V、U、W、L)
  • 世界のその他セグメント:収益予測、2021年~2031年
    • 他の精神障害の有病率の上昇
    • 回復予測(V、U、W、L)

第8章 流通チャネル別市場予測、2021年~2031年

  • 病院薬局セグメント市場予測、2021年~2031年
    • 最大の収益創出セグメント
    • 回復シナリオ(V、U、W、L)
  • 小売薬局セグメントの市場予測、2021年~2031年
    • 市場で最も急成長しているセグメント
    • 回復シナリオ(V、U、W、L)
  • その他のセグメント市場予測、2021年~2031年
    • ヘルスケアインフラストラクチャの発展が市場成長を促進
    • 回復シナリオ(V、U、W、L)

第9章 世界市場予測、2021年~2031年

  • 地域別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)

第10章 北米市場、2021年~2031年

  • 北米は世界の市場で最大の収益成長地域
  • 国別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)
  • 医薬品クラス別市場予測
  • 適応症別市場予測
  • 流通チャネル別市場予測
  • 米国市場予測、2021年~2031年
    • 医薬品承認数の増加
    • 高度に発達したヘルスケアインフラストラクチャの存在
    • 回復シナリオ(V、U、W、L):米国市場予測、2021年~2031年
  • カナダ市場予測、2021年~2031年
    • 北米地域で最も急速に成長する見込み
    • カナダでの製造および研究開発業務のメリット
    • 回復シナリオ(V、U、W、L):カナダ市場予測、2021年~2031年

第11章 欧州市場、2021年~2031年

  • 世界の市場で2番目に大きい市場
  • 国別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)
  • 医薬品クラス別市場予測
  • 適応症別市場予測
  • 流通チャネル別市場予測
  • ドイツ市場予測、2021年~2031年
    • この地域での高齢者人口の増加が、地域市場の成長を促進する見通し
    • 欧州で最も古いユニバーサルヘルスシステムの1つ
    • 回復シナリオ(V、U、W、L):ドイツ市場予測、2021年~2031年
  • 英国市場予測、2021年~2031年
    • 十分に発達したR&Dインフラストラクチャの存在
    • この地域における精神障害の有病率の増加
    • 回復シナリオ(V、U、W、L):英国市場予測、2021年~2031年
  • フランス市場予測、2021年~2031年
    • 手ごろな価格のヘルスケアサービスに対する需要の高まり
    • 革新的な医療と医薬品に対する需要の高まり
    • 回復シナリオ(V、U、W、L):フランス市場予測、2021年~2031年
  • イタリア市場予測、2021年~2031年
    • 医薬品製造のハブ
    • 精神障害の治療のための先進的治療法に対する需要の高まり
    • 回復シナリオ(V、U、W、L):イタリア市場予測、2021年~2031年
  • スペイン市場予測、2021年~2031年
    • 力強く成長するスペイン経済
    • 医薬品の需要は製薬業界の成長に影響されます
    • 回復シナリオ(V、U、W、L):スペイン市場予測、2021年~2031年
  • ロシア市場予測、2021年~2031年
    • 医薬品のアンメットニーズ
    • ヘルスケアインフラの開発に対する政府の支援
    • 回復シナリオ(V、U、W、L):ロシア市場予測、2021年~2031年
  • その他の欧州市場予測、2021年~2031年
    • 精神障害の有病率の増加
    • 回復シナリオ(V、U、W、L):その他の欧州市場予測、2021年~2031年

第12章 アジア太平洋地域市場、2021年~2031年

  • 最も急成長しているアジア太平洋地域市場
  • 国別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)
  • 医薬品クラス別市場予測
  • 適応症別市場予測
  • 流通チャネル別市場予測
  • 日本市場予測、2021年~2031年
    • 日本はアジア太平洋地域で最大の市場シェアを獲得
    • 政府のイニシアチブ
    • 回復シナリオ(V、U、W、L):日本市場予測、2021年~2031年
  • 中国市場予測、2021年~2031年
    • 大規模な老齢人口の存在
    • 中国での医療費の増加
    • 回復シナリオ(V、U、W、L):中国市場予測、2021年~2031年
  • インド市場予測、2021年~2031年
    • ヘルスケアインフラストラクチャの発展
    • 精神障害の有病率の増加
    • 回復シナリオ(V、U、W、L):インド市場予測、2021年~2031年
  • オーストラリア市場予測、2021年~2031年
    • 質の高い眼科医療施設へのアクセスを拡大するための政府プログラム
    • 確立されたヘルスケアインフラストラクチャ
    • 回復シナリオ(V、U、W、L):オーストラリア市場予測、2021年~2031年
  • 韓国市場予測、2021年~2031年
    • 人々の間でのヘルスケア意識の高まり
    • うつ病の有病率の増加
    • 回復シナリオ(V、U、W、L):韓国市場予測、2021年~2031年
  • その他のアジア太平洋地域市場予測、2021年~2031年
    • 可処分所得の増加
    • 回復シナリオ(V、U、W、L):その他のアジア太平洋地域市場予測、2021年~2031年

第13章 ラテンアメリカ市場、2021年~2031年

  • ラテンアメリカ市場
  • 国別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)
  • 医薬品クラス別市場予測
  • 適応症別市場予測
  • 流通チャネル別市場予測
  • ブラジル市場予測、2021年~2031年
    • ラテンアメリカで最も急速に成長している経済
    • 現地生産を維持するための政府のインセンティブ
    • 回復シナリオ(V、U、W、L):ブラジル市場予測、2021年~2031年
  • メキシコ市場予測、2021年~2031年
    • 米国よりも低い製造コスト
    • 民間および公共部門によって行われる有利なイニシアチブ
    • 回復シナリオ(V、U、W、L):メキシコ市場予測、2021年~2031年
  • アルゼンチン市場予測、2021年~2031年
    • 製薬業界のブーム
    • うつ病およびその他の精神障害薬の採用
    • 回復シナリオ(V、U、W、L):アルゼンチン市場予測、2021年~2031年
  • その他のラテンアメリカ市場予測、2021年~2031年
    • ヘルスケアインフラストラクチャの発展
    • 回復シナリオ(V、U、W、L):その他のラテンアメリカ市場予測、2021年~2031年

第14章 MEA市場、2021年~2031年

  • 精神障害の有病率の上昇
  • 国別市場予測、2021年~2031年
  • 回復シナリオ(V、U、W、L)
  • 医薬品クラス別市場予測
  • 適応症別市場予測
  • 流通チャネル別市場予測
  • 南アフリカ市場予測、2021年~2031年
    • この地域の製薬および製薬企業の注目の高まり
    • 支援的な政府のイニシアチブ
    • 回復シナリオ(V、U、W、L):南アフリカ市場予測、2021年~2031年
  • サウジアラビア市場予測、2021年~2031年
    • 巨大な成長機会の存在
    • 巨大な成長機会の存在
    • 回復シナリオ(V、U、W、L):サウジアラビア市場予測、2021年~2031年
  • その他のMEA市場予測、2021年~2031年
    • 大手企業の強い存在感
    • 精神障害の有病率の高まり
    • 回復シナリオ(V、U、W、L):その他のMEA市場予測、2021年~2031年

第15章 企業プロファイル

  • 企業シェア分析
  • 精神障害薬市場の最新動向、2017年~2020年
  • Novartis AG
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • GlaxoSmithKline Pharmaceuticals Ltd.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Pfizer Inc.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • AbbVie Inc.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Johnson & Johnson
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • AstraZeneca
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Otsuka Pharmaceuticals
    • 企業のスナップショット
    • 企業概要
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Eli Lilly and Company
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • H. Lundbeck A/S
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Takeda Pharmaceutical Company Ltd.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Bausch Health
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
  • Mallinckrodt Pharmaceuticals
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
  • Teva Pharmaceutical Industries Ltd.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年
  • Merck & Co., Inc.
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
  • Bristol-Myers Squibb
    • 企業のスナップショット
    • 企業概要
    • 財務分析
    • 製品のベンチマーク
    • 最新動向、2017年~2020年

第16章 結論と提言

  • 結論
  • 提言
図表

List of Tables

  • Table 1 Mental Disorder Types
  • Table 2 Global Mental Disorder Drugs Market, 2021 & 2031 (US$ bn, CAGR %)
  • Table 3 Worldwide Mental Disorders Prevalence, 2017
  • Table 4 Major M&A and Collaborations: Mental Disorder Drugs Market
  • Table 5 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
  • Table 6 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
  • Table 7 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
  • Table 8 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
  • Table 9 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
  • Table 10 Global Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 11 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 12 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 13 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 14 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 15 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 16 Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 17 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 18 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 19 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 20 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 21 Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 22 "V" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 23 "U" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 24 "W" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 25 "L" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 26 Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 27 "V" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 28 "U" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 29 "W" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 30 "L" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 31 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 32 "V" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 33 "U" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 34 "W" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 35 "L" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 36 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 37 "V" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 38 "U" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 39 "W" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 40 "L" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 41 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 42 "V" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 43 "U" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 44 "W" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 45 "L" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 46 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 47 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 48 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 49 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 50 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 51 Global Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 53 "V" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 54 "U" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 55 "W" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 56 "L" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 58 "V" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 59 "U" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 60 "W" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 61 "L" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 63 "V" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 64 "U" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 65 "W" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 66 "L" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 68 "V" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 69 "U" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 70 "W" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 71 "L" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 73 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 74 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 75 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 76 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 77 Global Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 88 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 89 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 90 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 91 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 92 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 93 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 94 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 95 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 96 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 97 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 98 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 99 North America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 100 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 101 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 102 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 103 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 104 North America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 105 North America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 117 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 118 Europe Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 119 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 120 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 121 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 122 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 123 Europe Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 124 Europe Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR %)
  • Table 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 161 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 163 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 164 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 165 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 166 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 167 Asia Pacific Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 168 Asia Pacific Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 200 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 201 Latin America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 202 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 203 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 1 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 204 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 205 Latin America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 206 Latin America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 207 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 208 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 213 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 218 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 223 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 2 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 228 MEA Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 229 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 230 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 231 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 232 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 233 MEA Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 234 MEA Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 235 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 236 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 237 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 241 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 242 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 246 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 247 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 251 Mental Disorder Drugs Market Recent Developments, 2017-2020
  • Table 252 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 253 Novatis AG: Product Benchmarking
  • Table 254 Novatis AG: Recent Developments, 2017-2020
  • Table 255 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 256 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
  • Table 257 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
  • Table 258 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 259 Pfizer Inc.: Product Benchmarking
  • Table 260 Pfizer Inc.: Recent Developments, 2017-2020
  • Table 261 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 262 AbbVie Inc.: Product Benchmarking
  • Table 263 AbbVie Inc.: Recent Developments, 2017-2020
  • Table 264 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 265 Johnson & Johnson: Product Benchmarking
  • Table 266 Johnson & Johnson: Recent Developments, 2017-2020
  • Table 267 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 268 AstraZeneca: Product Benchmarking
  • Table 269 AstraZeneca: Recent Developments, 2017-2020
  • Table 270 Otsuka Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 271 Otsuka Pharmaceuticals: Product Benchmarking
  • Table 272 Otsuka Pharmaceuticals: Recent Developments, 2017-2020
  • Table 273 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 274 Eli Lilly and Company: Product Benchmarking
  • Table 275 Eli Lilly and Company: Recent Developments, 2017-2020
  • Table 276 H. Lundbeck A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 277 H. Lundbeck A/S: Product Benchmarking
  • Table 278 H. Lundbeck A/S: Recent Developments, 2017-2020
  • Table 279 Takeda Pharmaceutical Company Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 280 Takeda Pharmaceutical Company Ltd.: Product Benchmarking
  • Table 281 Takeda Pharmaceutical Company Ltd.: Recent Developments, 2017-2020
  • Table 282 Bausch Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 283 Bausch Health: Product Benchmarking
  • Table 284 Mallinckrodt Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 285 Mallinckrodt Pharmaceuticals: Product Benchmarking
  • Table 286 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 287 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 288 Teva Pharmaceutical Industries Ltd.: Recent Developments, 2017-2020
  • Table 289 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 290 Merck & Co., Inc.: Product Benchmarking
  • Table 291 Bristol-Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 292 Bristol-Myers Squibb: Product Benchmarking
  • Table 293 Bristol-Myers Squibb: Recent Developments, 2017-2020

List of Figures

  • Figure 1 Global Mental Disorder Drugs Market Segmentation
  • Figure 2 Global Mental Disorder Drugs Market: Market Trends
  • Figure 3 Global Mental Disorder Drugs Market: SWOT Analysis
  • Figure 4 Global Mental Disorder Drugs Market: Porter's Five Forces Analysis
  • Figure 5 Global Mental Disorder Drugs Market: PEST Analysis
  • Figure 6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %)
  • Figure 7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "V" Shaped Recovery
  • Figure 8 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "U" Shaped Recovery
  • Figure 9 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "W" Shaped Recovery
  • Figure 10 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "L" Shaped Recovery
  • Figure 11 Global Mental Disorder Drugs Market Share Forecast by Drug Class, 2021, 2026, 2031 (%)
  • Figure 12 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 13 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 14 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 15 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 16 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 17 Global SNRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 18 "V" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 19 "U" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 20 "W" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 21 "L" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 22 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 23 "V" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 24 "U" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 25 "W" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 26 "L" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 27 Global TCAs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 28 "V" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 29 "U" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 30 "W" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 31 "L" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 32 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 33 "V" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 34 "U" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 35 "W" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 36 "L" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 37 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 38 "V" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 39 "U" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 40 "W" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 41 "L" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 42 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 43 "V" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 44 "U" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 45 "W" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 46 "L" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 47 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 48 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 49 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 50 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 51 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 53 "V" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 54 "U" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 55 "W" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 56 "L" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 58 "V" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 59 "U" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 60 "W" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 61 "L" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 63 "V" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 64 "U" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 65 "W" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 66 "L" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 68 "V" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 69 "U" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 70 "W" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 71 "L" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 73 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 74 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 75 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 76 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 77 Global Mental Disorder Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
  • Figure 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 88 Global Mental Disorder Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 89 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 90 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 91 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 92 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 93 Global Mental Disorder Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
  • Figure 94 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): "V" Shaped Recovery
  • Figure 95 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): "U" Shaped Recovery
  • Figure 96 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 97 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 98 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 99 North America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 100 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 101 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 102 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 103 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 104 North America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 105 North America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 117 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 118 Europe Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 119 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 120 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 121 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 122 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 123 Europe Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 124 Europe Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 161 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 163 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 164 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 165 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 166 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 167 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 168 Asia Pacific Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 200 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 201 Latin America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 202 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 203 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 204 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 205 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 206 Latin America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 207 Latin America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 208 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 213 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 218 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 223 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 228 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 229 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 230 MEA Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 231 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 232 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 233 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 234 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 235 MEA Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 236 MEA Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 237 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 241 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 242 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 246 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 247 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 251 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 252 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 253 Global Mental Disorder Drugs Market: Company Share Analysis, 2020
  • Figure 254 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 255 Novatis AG: Product Revenue Shares, 2019
  • Figure 256 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
  • Figure 257 Novatis AG: Regional Revenue Shares, 2019
  • Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
  • Figure 260 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
  • Figure 261 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
  • Figure 262 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 263 Pfizer Inc.: Product Revenue Shares, 2019
  • Figure 264 Pfizer Inc.: Regional Revenue Shares, 2019
  • Figure 265 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 266 AbbVie Inc.: Product Revenue Shares, 2019
  • Figure 267 AbbVie Inc.: Regional Revenue Shares, 2019
  • Figure 268 Johnson & Johnson: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 269 Johnson & Johnson: Pharmaceutical Segment Revenue Shares, 2019
  • Figure 270 Johnson & Johnson: Business Segment Revenue Shares, 2019
  • Figure 271 AstraZeneca: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 272 AstraZeneca: Product Revenue Shares, 2019
  • Figure 273 AstraZeneca: Regional Revenue Shares, 2019
  • Figure 274 Eli Lilly and Company: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 275 Eli Lilly and Company: Product Revenue Shares, 2019
  • Figure 276 Eli Lilly and Company: Regional Revenue Shares, 2019
  • Figure 277 H. Lundbeck A/S: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 278 H. Lundbeck A/S: Regional Revenue Shares, 2019
  • Figure 279 Takeda Pharmaceutical Company Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 280 Takeda Pharmaceutical Company Ltd.: Regional Revenue Shares, 2019
  • Figure 281 Bausch Health: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 282 Bausch Health: Product Revenue Shares, 2019
  • Figure 283 Bausch Health: Regional Revenue Shares, 2019
  • Figure 284 Mallinckrodt Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 285 Mallinckrodt Pharmaceuticals: Product Revenue Shares, 2019
  • Figure 286 Mallinckrodt Pharmaceuticals: Regional Revenue Shares, 2019
  • Figure 287 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 288 Teva Pharmaceutical Industries Ltd.: Product Revenue Shares, 2019
  • Figure 289 Teva Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2019
  • Figure 290 Merck & Co., Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 291 Merck & Co., Inc.: Product Revenue Shares, 2019
  • Figure 292 Merck & Co., Inc.: Regional Revenue Shares, 2019
  • Figure 293 Bristol-Myers Squibb: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 294 Bristol-Myers Squibb: Regional Revenue Shares, 2019

Companies Profiled in the Report

  • AbbVie Inc.
  • AstraZeneca
  • Bausch Health
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Johnson and Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • List of Companies Mentioned in the Report
  • AbbVie Inc.
  • Actelion Ltd
  • Allergan plc
  • AstraZeneca
  • Aurobindo Pharma
  • Bausch Health
  • Bristol Myers Squibb Company
  • Cadent Therapeutics
  • Celgene Corporation
  • Concordia Pharms Inc
  • Dr. Reddy's Labs
  • Eli Lilly and Company
  • Gedeon Richter Plc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Janssen Holding GmbH
  • Janssen Pharmaceutical
  • Janssen Research & Development, LLC
  • Jazz Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Orchard Therapeutics
  • Osmotica Pharmaceutical Corp.
  • Otsuka Pharmaceutical Co., Ltd.
  • Par Pharmaceutical
  • Pear Therapeutics, Inc.,
  • Pfizer Inc.
  • Proteus Digital Health (Proteus)
  • Sandoz
  • Sanofi SA (France)
  • Sebela International Ltd.
  • Somerset Pharmaceuticals, Inc.
  • Strateos, Inc.
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Teva Canada Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals

List of Organizations Mentioned in the Report

  • Australian Government
  • Australian Institute of Health and Welfare
  • CAMH (Centre for Addiction and Mental Health)
  • Centers for Disease Control and Prevention (CDC)
  • Child Mind Institute
  • China's Ministry of Finance
  • Chinese government
  • European Union
  • EXIM bank
  • FDA Centre's for Drug Evaluation and Research
  • French Government
  • Government of Japan
  • Health Ministry (Italy)
  • Institute for Healthcare Improvement (IHI)
  • Italian Industry Group Farmindustria
  • Japanese Ministry of Health, Labour and Welfare
  • King Salman Humanitarian Aids & Relief Center
  • MHFA England
  • National Development and Reform Commission (NDRC)
  • National Institute of Health (NIH)
  • National Mental Health Institute
  • NCBI
  • NHS England
  • NHS England 's House of Care
  • Organisation for Economic Co-operation and Development (OECD)
  • Saudi Export Development Authority
  • US government
  • WHO
  • World Bank
  • World Economic Forum (WEF)
目次
Product Code: PHA1072

Title:
Mental Disorder Drugs Market Report 2021-2031
Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios.

Mental Disorder Drugs Market - reveals latest trends, opportunities, predicted revenues, and competitive analysis. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.

Global mental disorder drugs market is projected to reach at a market value of US$xx billion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of mental disorders including depression, bipolar disorder, anxiety, and schizophrenia is a major factor that drives the demand for mental disorder drugs. Other key drivers boosting the market growth are growing mental health awareness in developing countries; adoption of mental disorder drugs for treatment & maintenance therapy; and rising R&D investment by the leading pharmaceutical companies in the area of mental health. In addition, the COVID-19 pandemic has a significant impact on the mental disorder drugs market. The COVID-19 pandemic has resulted in a growing incidence of mental disorders due to unemployment, financial crisis, health issues, and stress. Thus, the demand for mental disorder drugs is expected to rise during the forecast period.

Visiongain's report shows you the potential revenues streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the mental disorder drugs industry.

How this report will benefit you

Visiongain's new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit in the near future. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
  • It also includes growth rates for different 5 regional markets along with 18 countries and COVID-19 impact analysis on each market
  • The profiles of the top 15 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
  • The COVID-19 has a positive impact on the mental disorder drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.

Discover sales forecasts for the global and regional market forecasts from 2021-2031

Along with revenue prediction for the overall global market, there is segmentation by region for 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA and 20 major countries.

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class

  • SSRIs
  • SNRIs
  • Atypical Antipsychotics
  • TCAs
  • SARIs
  • Benzodiazepines
  • MAOIs
  • Others

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication

  • Depression
  • Schizophrenia
  • Bipolar disorder
  • Post-traumatic Stress Disorder
  • Others

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional market revenue and growth forecasts from 2021 to 2031:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Detailed profiles of 15 leading companies that are operating in the market

The report includes profiles of 15 major companies involved in the mental disorder drugs market. The companies profiled in this report include: AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.

Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 429-page report delivers you with the following knowledge:

  • Revenue forecasts from 2021 to 2031 for the global mental disorder drugs market and subsegments (by drug class, indication, distribution channel, and region)- discover the industry's prospects, finding the most lucrative areas for investments and revenue generation
  • Detailed profiles of top 15 mental disorder drugs manufacturers, with financial overviews for net revenues, operating income, R&D investment, and segment revenues
  • Revenue forecasts from 2021 to 2031 for 5 regional markets - See forecasts for the mental disorder drugs market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Information found nowhere else

With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the mental disorder drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.

The Mental Disorder Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the mental disorder drugs industry.

Buy our report today Mental Disorder Drugs Market Report 2021-2031: Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios”. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Mental Disorder Drugs Market
    • 1.1.1 What Is Mental Disorder?
    • 1.1.2 Types of Mental Disorders
    • 1.1.3 Prevalence and Mortality for Mental Disorders
  • 1.2 Why You Should Read This Report
  • 1.3 What This Report Delivers
  • 1.4 Key Questions Answered By This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation & Forecast Methodology
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2 Executive Summary

3 Market Dynamics

  • 3.1 Drivers
    • 3.1.1 Development of Advanced Mental Disorder Drugs
    • 3.1.2 Increasing Prevalence of Mental Disorders
    • 3.1.3 Escalating of Mental Healthcare Awareness
  • 3.2 Restraints
    • 3.2.1 Increasing Development of Novel Drugs
    • 3.2.2 Social Stigma of Mental Disorders
    • 3.2.3 Stringent Regulatory Guidelines for New Drug Approval
  • 3.3 Opportunities
    • 3.3.1 Growing Demand for Cutting-Edge Therapeutic Treatments for Mental Disorders to Aid Market Growth
    • 3.3.2 Increase in Geriatric Population
  • 3.4 Trends
    • 3.4.1 Mergers, Agreements, and Acquisitions by the Market Players
    • 3.4.2 Expected Launch of New Drugs is Expected to Drive the Market Growth
  • 3.5 SWOT Analysis
    • 3.5.1 Strengths: The Most Dynamic Area of the Mental Disorders Market
    • 3.5.2 Weaknesses
    • 3.5.3 Opportunities
      • 3.5.3.1 Increasing Mergers & Acquisitions and Collaborations
      • 3.5.3.2 Large Amount of R&D Investment
    • 3.5.4 Threats
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Supplier: Moderate
    • 3.6.2 Bargaining Power of Buyer: Moderate
    • 3.6.3 Competitive Rivalry: High
    • 3.6.4 Threat of New Entrants: Moderate
    • 3.6.5 Threat of Substitutes: Moderate
  • 3.7 PEST Analysis
    • 3.7.1 Political Factors Impacting Mental Disorder Drugs Market
    • 3.7.2 Economic Factors Impacting Mental Disorder Drugs Market
    • 3.7.3 Social Factors Impacting Mental Disorder Drugs Market
    • 3.7.4 Technological Factors Impacting Mental Disorder Drugs Market

4 Global Mental Disorder Drugs Market Forecast, 2021-2031

  • 4.1 Global Mental Disorder Drugs Market Forecast 2021-2031

5 COVID-19 Impact: Global Mental Disorder Drugs Market

  • 5.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
  • 5.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
  • 5.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
  • 5.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth

6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Drug Class

  • 6.1 Global SSRIs Segment: Revenue Forecast 2021-2031
    • 6.1.1 Largest Revenue Grossing Segment
    • 6.1.2 Recovery Forecasts (V, U, W, L)
  • 6.2 Global SNRIs Segment: Revenue Forecast 2021-2031
    • 6.2.1 Increase in Adoption of These Drugs for the Treatment of Mental Disorders
    • 6.2.2 Recovery Forecasts (V, U, W, L)
  • 6.3 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031
    • 6.3.1 Atypical Antipsychotics Segment is Expected to Grow at a Lucrative Growth Rate
    • 6.3.2 Recovery Forecasts (V, U, W, L)
  • 6.4 Global TCAs Segment: Revenue Forecast 2021-2031
    • 6.4.1 TCAs Play an In the Treatment of Severe Depression
    • 6.4.2 Recovery Forecasts (V, U, W, L)
  • 6.5 Global SARIs Segment: Revenue Forecast 2021-2031
    • 6.5.1 SARIs Are Mainly Used For The Treatment MDD
    • 6.5.2 Recovery Forecasts (V, U, W, L)
  • 6.6 Global Benzodiazepines Segment: Revenue Forecast 2021-2031
    • 6.6.1 Benzodiazepines Segment is Presumed to Witness Moderate Growth over the Forecast Period
    • 6.6.2 Recovery Forecasts (V, U, W, L)
  • 6.7 Global MAOIs Segment: Revenue Forecast 2021-2031
    • 6.7.1 MAOIs Segment Expected To Witness Lucrative CAGR during the Forecast Period
    • 6.7.2 Recovery Forecasts (V, U, W, L)
  • 6.8 Global Others Segment: Revenue Forecast 2021-2031
    • 6.8.1 Growing Demand for Advanced Drugs Is Expected to Propel the Segment Growth
    • 6.8.2 Recovery Forecasts (V, U, W, L)

7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Indication

  • 7.1 Global Depression Segment: Revenue Forecast 2021-2031
    • 7.1.1 Largest Revenue Grossing Segment
    • 7.1.2 Recovery Forecasts (V, U, W, L)
  • 7.2 Global Schizophrenia Segment: Revenue Forecast 2021-2031
    • 7.2.1 Mounting Prevalence of Schizophrenia Worldwide Will Drive the Segment Growth
    • 7.2.2 Recovery Forecasts (V, U, W, L)
  • 7.3 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031
    • 7.3.1 Adoption of Generic Drugs for the Treatment of Bipolar Disorder
    • 7.3.2 Recovery Forecasts (V, U, W, L)
  • 7.4 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031
    • 7.4.1 Growing R&D expenditure in the development of therapeutically advanced mental disorder drugs
    • 7.4.2 Recovery Forecasts (V, U, W, L)
  • 7.5 Global Others Segment: Revenue Forecast 2021-2031
    • 7.5.1 Rising Prevalence of Other Mental Disorders
    • 7.5.2 Recovery Forecasts (V, U, W, L)

8 Mental Disorder Drugs Market by Distribution Channel Forecast, 2021-2031

  • 8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
    • 8.1.1 Largest Revenue Generating Segment
    • 8.1.2 Recovery Scenarios (V, U, W, L)
  • 8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
    • 8.2.1 Fastest Growing Segment in the Market
    • 8.2.2 Recovery Scenarios (V, U, W, L)
  • 8.3 Others Segment Market Forecast, 2021-2031
    • 8.3.1 Developing Healthcare Infrastructure Is Expected To Drive the Market Growth
    • 8.3.2 Recovery Scenarios (V, U, W, L)

9 Global Mental Disorder Drugs Market Forecast, 2021-2031

  • 9.1 Global Mental Disorder Drugs Market by Region Forecast 2021-2031
  • 9.2 Recovery Scenarios (V, U, W, L)

10 North America Mental Disorder Drugs Market, 2021-2031

  • 10.1 North America is The Largest Revenue Grossing Region in the Global Market
  • 10.2 North America Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 10.3 Recovery Scenarios (V, U, W, L)
  • 10.4 North America Mental Disorder Drugs Market Forecast by Drug Class
  • 10.5 North America Mental Disorder Drugs Market Forecast by Indication
  • 10.6 North America Mental Disorder Drugs Market Forecast by Distribution Channel
  • 10.7 U.S. Mental Disorder Drugs Market Forecast, 2021-2031
    • 10.7.1 Rise in the Number of Drug Approvals
    • 10.7.2 Presence of Highly Developed Healthcare Infrastructure
    • 10.7.3 Recovery Scenarios (V, U, W, L): U.S. Mental Disorder Drugs Market Forecast, 2021-2031
  • 10.8 Canada Mental Disorder Drugs Market Forecast, 2021-2031
    • 10.8.1 Anticipated To Witness the Fastest Growth in the North America Region
    • 10.8.2 Benefits of Manufacturing and R&D Operations in Canada
    • 10.8.3 Recovery Scenarios (V, U, W, L): Canada Mental Disorder Drugs Market Forecast, 2021-2031

11 Europe Mental Disorder Drugs Market, 2021-2031

  • 11.1 Second Largest Market in the Global Market
  • 11.2 Europe Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 11.3 Recovery Scenarios (V, U, W, L)
  • 11.4 Europe Mental Disorder Drugs Market Forecast by Drug Class
  • 11.5 Europe Mental Disorder Drugs Market Forecast by Indication
  • 11.6 Europe Mental Disorder Drugs Market Forecast by Distribution Channel
  • 11.7 Germany Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.7.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
    • 11.7.2 One of the Oldest Universal Health Systems within Europe
    • 11.7.3 Recovery Scenarios (V, U, W, L): Germany Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.8 UK Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.8.1 Presence of Well-Developed R&D Infrastructure
    • 11.8.2 Increasing Prevalence of Mental Disorders in This Region
    • 11.8.3 Recovery Scenarios (V, U, W, L): UK Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.9 France Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.9.1 Growing Demand For Affordable Healthcare Services
    • 11.9.2 Growing Demand for Innovative Medicine and Pharmaceutical
    • 11.9.3 Recovery Scenarios (V, U, W, L): France Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.10 Italy Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.10.1 Pharmaceutical Manufacturing Hub
    • 11.10.2 Growing Demand for Advanced Therapies for the Treatment of Mental Disorders
    • 11.10.3 Recovery Scenarios (V, U, W, L): Italy Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.11 Spain Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.11.1 Spanish Economy Is Growing Strong
    • 11.11.2 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
    • 11.11.3 Recovery Scenarios (V, U, W, L): Spain Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.12 Russia Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.12.1 Unmet Pharmaceutical Needs
    • 11.12.2 Government Support For Development of the Healthcare Infrastructure
    • 11.12.3 Recovery Scenarios (V, U, W, L): Russia Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.13 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.13.1 Increasing Prevalence of Mental Disorders
    • 11.13.2 Recovery Scenarios (V, U, W, L): Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031

12 Asia Pacific Mental Disorder Drugs Market, 2021-2031

  • 12.1 Asia Pacific is the Fastest Growing Market
  • 12.2 Asia Pacific Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 12.3 Recovery Scenarios (V, U, W, L)
  • 12.4 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class
  • 12.5 Asia Pacific Mental Disorder Drugs Market Forecast by Indication
  • 12.6 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel
  • 12.7 Japan Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.7.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
    • 12.7.2 Government Initiatives
    • 12.7.3 Recovery Scenarios (V, U, W, L): Japan Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.8 China Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.8.1 Presence of Large Geriatric Population
    • 12.8.2 Increasing Healthcare Spending In China
    • 12.8.3 Recovery Scenarios (V, U, W, L): China Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.9 India Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.9.1 Developing Healthcare Infrastructure
    • 12.9.2 Increasing Prevalence of Mental Disorders
    • 12.9.3 Recovery Scenarios (V, U, W, L): India Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.10 Australia Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.10.1 Government Programs to Expand Access to Quality Eye Care Facilities
    • 12.10.2 Well Established Healthcare Infrastructure
    • 12.10.3 Recovery Scenarios (V, U, W, L): Australia Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.11 South Korea Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.11.1 Growing Healthcare Awareness among People
    • 12.11.2 Increasing Prevalence of Depression
    • 12.11.3 Recovery Scenarios (V, U, W, L): South Korea Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.12 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.12.1 Rising Disposable Income
    • 12.12.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031

13 Latin America Mental Disorder Drugs Market, 2021-2031

  • 13.1 Latin America Mental Disorder Drugs Market
  • 13.2 Latin America Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 13.3 Recovery Scenarios (V, U, W, L)
  • 13.4 Latin America Mental Disorder Drugs Market Forecast by Drug Class
  • 13.5 Latin America Mental Disorder Drugs Market Forecast by Indication
  • 13.6 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel
  • 13.7 Brazil Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.7.1 Fastest Growing Economies in Latin America
    • 13.7.2 Government Incentives to Keep Manufacturing Local
    • 13.7.3 Recovery Scenarios (V, U, W, L): Brazil Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.8 Mexico Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.8.1 Lower Manufacturing Costs than In the US
    • 13.8.2 Favourable Initiatives Undertaken By Private and Public Sectors
    • 13.8.3 Recovery Scenarios (V, U, W, L): Mexico Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.9 Argentina Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.9.1 Boom in Pharmaceutical Industry
    • 13.9.2 Adoption of Depression and Other Mental Disorders Drugs
    • 13.9.3 Recovery Scenarios (V, U, W, L): Argentina Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.10 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.10.1 Developing Healthcare Infrastructure
    • 13.10.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031

14 MEA Mental Disorder Drugs Market, 2021-2031

  • 14.1 Rising Prevalence of Mental Disorders
  • 14.2 MEA Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 14.3 Recovery Scenarios (V, U, W, L)
  • 14.4 MEA Mental Disorder Drugs Market Forecast by Drug Class
  • 14.5 MEA Mental Disorder Drugs Market Forecast by Indication
  • 14.6 MEA Mental Disorder Drugs Market Forecast by Distribution Channel
  • 14.7 South Africa Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.7.1 Increasing Focus of Pharmaceutical & Pharmaceutical Companies in This Region
    • 14.7.2 Supportive Government Initiatives
    • 14.7.3 Recovery Scenarios (V, U, W, L): South Africa Mental Disorder Drugs Market Forecast, 2021-2031
  • 14.8 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.8.1 Presence of Huge Growth Opportunities
    • 14.8.2 Presence of Huge Growth Opportunities
    • 14.8.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
  • 14.9 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.9.1 Strong Presence Of Leading Companies
    • 14.9.2 Growing Prevalence of Mental Disorders
    • 14.9.3 Recovery Scenarios (V, U, W, L): Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031

15 Company Profiles

  • 15.1 Company Share Analysis
  • 15.2 Mental Disorder Drugs Market Recent Developments, 2017-2020
  • 15.3 Novartis AG
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2015-2019
      • 15.3.3.2 Product Revenue Shares, 2019
      • 15.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
      • 15.3.3.4 Regional Revenue Shares, 2019
    • 15.3.4 Product Benchmarking
    • 15.3.5 Recent Developments, 2017-2020
  • 15.4 GlaxoSmithKline Pharmaceuticals Ltd.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2015-2019
      • 15.4.3.2 Product Revenue Shares, 2019
      • 15.4.3.3 Pharmaceuticals Segment Revenue Shares, 2019
      • 15.4.3.4 Regional Revenue Shares, 2019
    • 15.4.4 Product Benchmarking
    • 15.4.5 Recent Developments, 2017-2020
  • 15.5 Pfizer Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2015-2019
      • 15.5.3.2 Product Revenue Shares, 2019
      • 15.5.3.3 Regional Revenue Shares, 2019
    • 15.5.4 Product Benchmarking
    • 15.5.5 Recent Developments, 2017-2020
  • 15.6 AbbVie Inc.
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2015-2019
      • 15.6.3.2 Product Revenue Shares, 2019
      • 15.6.3.3 Regional Revenue Shares, 2019
    • 15.6.4 Product Benchmarking
    • 15.6.5 Recent Developments, 2017-2020
  • 15.7 Johnson & Johnson
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2015-2019
      • 15.7.3.2 Product Revenue Shares, 2019
      • 15.7.3.3 Regional Revenue Shares, 2019
    • 15.7.4 Product Benchmarking
    • 15.7.5 Recent Developments, 2017-2020
  • 15.8 AstraZeneca
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2015-2019
      • 15.8.3.2 Product Revenue Shares, 2019
      • 15.8.3.3 Regional Revenue Shares, 2019
    • 15.8.4 Product Benchmarking
    • 15.8.5 Recent Developments, 2017-2020
  • 15.9 Otsuka Pharmaceuticals
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Recent Developments, 2017-2020
  • 15.10 Eli Lilly and Company
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2015-2019
      • 15.10.3.2 Product Revenue Shares, 2019
      • 15.10.3.3 Regional Revenue Shares, 2019
    • 15.10.4 Product Benchmarking
    • 15.10.5 Recent Developments, 2017-2020
  • 15.11 H. Lundbeck A/S
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2015-2019
      • 15.11.3.2 Regional Revenue Shares, 2019
    • 15.11.4 Product Benchmarking
    • 15.11.5 Recent Developments, 2017-2020
  • 15.12 Takeda Pharmaceutical Company Ltd.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2015-2019
      • 15.12.3.2 Regional Revenue Shares, 2019
    • 15.12.4 Product Benchmarking
    • 15.12.5 Recent Developments, 2017-2020
  • 15.13 Bausch Health
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2015-2019
      • 15.13.3.2 Product Revenue Shares, 2019
      • 15.13.3.3 Regional Revenue Shares, 2019
    • 15.13.4 Product Benchmarking
  • 15.14 Mallinckrodt Pharmaceuticals
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2015-2019
      • 15.14.3.2 Product Revenue Shares, 2019
      • 15.14.3.3 Regional Revenue Shares, 2019
    • 15.14.4 Product Benchmarking
  • 15.15 Teva Pharmaceutical Industries Ltd.
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2015-2019
      • 15.15.3.2 Product Revenue Shares, 2019
      • 15.15.3.3 Regional Revenue Shares, 2019
    • 15.15.4 Product Benchmarking
    • 15.15.5 Recent Developments, 2017-2020
  • 15.16 Merck & Co., Inc.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2015-2019
      • 15.16.3.2 Product Revenue Shares, 2019
      • 15.16.3.3 Regional Revenue Shares, 2019
    • 15.16.4 Product Benchmarking
  • 15.17 Bristol-Myers Squibb
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2015-2019
      • 15.17.3.2 Regional Revenue Shares, 2019
    • 15.17.4 Product Benchmarking
    • 15.17.5 Recent Developments, 2017-2020

16 Conclusion and Recommendations

  • 16.1 Conclusion
  • 16.2 Recommendations